Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

被引:3
作者
Gonzalez, Amalia [1 ]
Walker, Evan J. [2 ,3 ]
Van Loon, Katherine [2 ,3 ]
Cinar, Pelin [2 ,3 ]
Atreya, Chloe E. [2 ,3 ]
机构
[1] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA
[3] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
关键词
Chemotherapy-induced neurotoxicity; oxaliplatin; colorectal cancer; gastrointestinal cancer; INDUCED PERIPHERAL NEUROPATHY; GEMCITABINE PLUS OXALIPLATIN; III COLON-CANCER; ADJUVANT TREATMENT; COLORECTAL-CANCER; DOUBLE-BLIND; STAGE-II; FLUOROURACIL; LEUCOVORIN; CHEMOTHERAPY;
D O I
10.21873/anticanres.14019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Oxaliplatin-induced neurotoxicity (OIN) can be severe and dose-limiting with clinically significant symptoms that persist for years. Few published reports have described postoperative exacerbation of OIN and more longitudinal data are needed to better characterize the phenomenon. Patients and Methods: We identified 13 patients diagnosed with colon (n=7), rectal (n=4) or pancreatic (n=2) cancer who experienced postoperative OIN exacerbation at our medical center. Charts were reviewed for demographic and clinical data regarding OIN. Results: OIN exacerbation was documented 0.5-7.0 months after the first surgery following oxaliplatin exposure, with a median duration of 10.6 months (range=1.4-86.1 months). OIN exacerbation persisted in 3/13 patients at last follow-up, and improved to pre-operative levels in 6/13 patients (with complete resolution in 4/13) within a median of 3.6 months from initial exacerbation. Conclusion: Given the widespread use of oxaliplatin in neoadjuvant and first-line treatment for gastrointestinal cancers, further study is warranted to prospectively and systematically define risks for postoperative OIN exacerbation.
引用
收藏
页码:865 / 871
页数:7
相关论文
共 39 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer The AIO-FLOT3 Trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Illerhaus, Gerald ;
Martens, Uwe M. ;
Stoehlmacher, Jan ;
Schmalenberg, Harald ;
Luley, Kim B. ;
Prasnikar, Nicole ;
Egger, Matthias ;
Probst, Stephan ;
Messmann, Helmut ;
Moehler, Markus ;
Fischbach, Wolfgang ;
Hartmann, Joerg T. ;
Mayer, Frank ;
Hoeffkes, Heinz-Gert ;
Koenigsmann, Michael ;
Arnold, Dirk ;
Kraus, Thomas W. ;
Grimm, Kersten ;
Berkhoff, Stefan ;
Post, Stefan ;
Jager, Elke ;
Bechstein, Wolf ;
Ronellenfitsch, Ulrich ;
Moenig, Stefan ;
Hofheinz, Ralf D. .
JAMA ONCOLOGY, 2017, 3 (09) :1237-1244
[3]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]   Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study [J].
André, T ;
Tournigand, C ;
Rosmorduc, O ;
Provent, S ;
Maindrault-Goebel, F ;
Avenin, D ;
Selle, F ;
Paye, F ;
Hannoun, L ;
Houry, S ;
Gayet, B ;
Lotz, JP ;
de Gramont, A ;
Louvet, C .
ANNALS OF ONCOLOGY, 2004, 15 (09) :1339-1343
[5]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[6]   Clinical pattern and associations of oxaliplatin acute neurotoxicity [J].
Argyriou, Andreas A. ;
Cavaletti, Guido ;
Briani, Chiara ;
Velasco, Roser ;
Bruna, Jordi ;
Campagnolo, Marta ;
Alberti, Paola ;
Bergamo, Francesca ;
Cortinovis, Diego ;
Cazzaniga, Marina ;
Santos, Cristina ;
Papadimitriou, Konstantinos ;
Kalofonos, Haralabos P. .
CANCER, 2013, 119 (02) :438-444
[7]  
Bao T, 2019, J ALTERN COMPLEM MED, V25, DOI [10.1089/acm.2019.29074.abstracts, DOI 10.1089/ACM.2019.29074]
[8]   A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma [J].
Bao, Ting ;
Goloubeva, Olga ;
Pelser, Colleen ;
Porter, Neil ;
Primrose, James ;
Hester, Lisa ;
Sadowska, Mariola ;
Lapidus, Rena ;
Medeiros, Michelle ;
Lao, Lixing ;
Dorsey, Susan G. ;
Badros, Ashraf Z. .
INTEGRATIVE CANCER THERAPIES, 2014, 13 (05) :396-404
[9]   Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer [J].
Cercek, Andrea ;
Roxburgh, Campbell S. D. ;
Strombom, Paul ;
Smith, J. Joshua ;
Temple, Larissa K. F. ;
Nash, Garrett M. ;
Guillem, Jose G. ;
Paty, Philip B. ;
Yaeger, Rona ;
Stadler, Zsofia K. ;
Seier, Kenneth ;
Gonen, Mithat ;
Segal, Neil H. ;
Reidy, Diane L. ;
Varghese, Anna ;
Shia, Jinru ;
Vakiani, Efsevia ;
Wu, Abraham J. ;
Crane, Christopher H. ;
Gollub, Marc J. ;
Garcia-Aguilar, Julio ;
Saltz, Leonard B. ;
Weiser, Martin R. .
JAMA ONCOLOGY, 2018, 4 (06)
[10]   Oxaliplatin-associated neuropathy: A review [J].
Cersosimo, RJ .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) :128-135